AbCellera Biologics Inc.
ABCL
$10.97
$0.625.94%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -28.41% | -382.56% | 84.34% | -64.48% | 23.88% |
| Total Depreciation and Amortization | 1.48% | 9.28% | 9.45% | 2.49% | 6.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 17.64% | 15.11% | -18.96% | 27.87% | -29.03% |
| Change in Net Operating Assets | 515.12% | 71.00% | -154.83% | -7.95% | -260.58% |
| Cash from Operations | 177.33% | 3.51% | 33.94% | -62.31% | -180.46% |
| Capital Expenditure | 44.35% | 61.08% | -10.25% | 33.20% | -25.66% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 163.40% | -125.01% | 87.12% | 346.21% | -199.33% |
| Cash from Investing | 145.22% | -133.38% | 105.93% | 214.70% | -500.89% |
| Total Debt Issued | -200.00% | -31.66% | 39.32% | 226.53% | -200.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -3,421.43% | -107.01% | -- |
| Cash from Financing | -11.11% | 74.78% | -44.18% | 318.43% | -156.53% |
| Foreign Exchange rate Adjustments | -1,031.58% | -113.10% | 153.31% | -171.48% | 28.98% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 184.02% | -214.84% | 582.86% | 86.12% | -2,372.32% |